ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1623

Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus

Julie Ducreux1, Séverine Nieuwland2, Frédéric A. Houssiau1 and Bernard R. Lauwerys1, 1Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, 2Institut de Recherche Expérimentale et Clinique, Pôle de pathologies rhumatismales, Université catholique de Louvain, Brussels, Belgium

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: B cells, flow cytometry and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies

Session Type: Abstract Submissions (ACR)

Background/Purpose: systemic lupus erythematosus (SLE) is characterized by a break of tolerance to autoantigens, and polyclonal activation of B cells. We performed multicolor flow cytometry analyses of B cell subsets in SLE patients and controls, in order to increase our understanding of the B cell activation steps characteristic of the disease.

Methods: PBMC from 16 SLE patients and 5 controls were analyzed using the following flow cytometry markers : CD5, IgD, CD27, CD20, CD19, CD38, CD95 and intracellular survivin, and their control isotypes. The data were acquired using a BD FacsCantoII and analyzed using FlowJo software. Serum C3 concentrations were retrieved from the medical records of the patients.

Results: SLE patients had significantly less CD19+CD20+IgD+CD27- naive B cells compared to controls (40.5 ± 30.7 versus 70.4 ± 8.5 % of total B cells, p = 0.048). By contrast, proportions of CD19+CD20+IgD-CD27- double negative (11.6 ± 8.8 versus 4.2 ± 1.6 %, p = 0.029) and CD19+CD20-CD38+ plasma cells (11.5 ± 18,4 versus 1.5 ± 1.0 %, p = 0.015) were significantly higher in SLE patients compared to controls. Proportions of CD19+CD20+IgD-CD27+ conventional memory B cells were also higher in SLE patients, but the difference was not significant (24.5 ± 18.7 versus 11.9 ± 4.4 %, p = 0.15).

Percentage of CD95 (Fas) positive cells was significantly higher in SLE naive (24.5 ± 17,4 versus 2.4 ± 1.3 %, p = 0.001), but also in double negative B cells compared to controls. Almost all SLE and control plasma cells expressed CD95. Strikingly, expression of CD95 on naive B cells correlated negatively with the proportion of naive B cells themselves (r = -0.50, p = 0.022), and positively with the proportions of double negative (r = 0.46, p = 0.034) and plasma cells (r = 0.57, p = 0.007).

In all B cell subsets, expression of CD95 displayed a significant positive correlation with intracellular expression of survivin (r = 0.63, p = 0.002), a cell proliferation and anti-apoptotic marker. Finally, we observed a significant negative correlation between both CD95 (r = -0.53, p = 0.036) or survivin (r = -0.50, p = 0.048) expression in naive B cells and serum C3.

Conclusion: CD95 expression on naive B cells is associated with a switch to double negative and plasma cells in the peripheral blood of SLE patients. The positive correlation between CD95 and survivin expression in SLE B cell subsets confirms that CD95 is a marker of B cell activation in SLE. Activation (CD95 and survivin expression) of naive B cells correlates with disease activity. Further studies on additional cross-sectional and longitudinal samples are ongoing.


Disclosure:

J. Ducreux,
None;

S. Nieuwland,
None;

F. A. Houssiau,
None;

B. R. Lauwerys,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-cd95-fas-expression-on-naive-b-cells-is-associated-with-a-switch-to-double-negative-and-plasma-cells-in-the-peripheral-blood-and-correlates-with-disease-activity-in-systemic-lupus-erythem/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology